Literature DB >> 18568900

Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function.

Kathryn DeRoche1, Marilyn Welsh.   

Abstract

Studies published from 1980 through 2004, which explored intelligence and executive function outcomes in early-treated PKU, were included in the present meta-analysis. The objective of this study was to examine the degree of difference between early-treated PKU and unaffected control groups (primarily non-familial controls), known as effect size, for various components of measured intelligence (i.e., full-scale, verbal, performance, and "other") and executive function (i.e., planning, working memory, inhibition, flexibility, and "other"). Secondly, in the case of heterogeneity among observed effect sizes, the moderator variables of "years since publication" and "measurement tools" were examined for their potential contribution to this heterogeneity. Thirty-three primary studies, with a total 200 outcomes meeting our inclusionary and exclusionary criteria, were meta-analyzed using Hedges g for effect size to correct for small samples in primary studies. The effect sizes for intelligence outcomes were "small" to "moderate" falling in the range of .20 to .42, with no significant heterogeneity among outcomes. Effect sizes for executive function and its various component processes were in the "moderate" and "large range" falling between .591 (planning) and 1.15 (flexibility). Significant heterogeneity among the executive function effect sizes was identified, and both "years since publication" and "measurement tools" were found to be significant moderators. Studies published more recently exhibited larger effect sizes, and particular executive function tasks demonstrated larger effect sizes than other tests. The results are discussed in terms of the contributions this meta-analysis makes to our understanding of neurocognitive outcomes in early-treated PKU, as well as suggestions for the conduct and reporting of future research in this area.

Entities:  

Mesh:

Year:  2008        PMID: 18568900     DOI: 10.1080/87565640802101482

Source DB:  PubMed          Journal:  Dev Neuropsychol        ISSN: 1532-6942            Impact factor:   2.253


  36 in total

1.  A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study.

Authors:  S H L Yi; J A Kable; M L Evatt; R H Singh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-10-14       Impact factor: 4.006

Review 2.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

3.  Activity restriction and depression in medical patients and their caregivers: a meta-analysis.

Authors:  Brent T Mausbach; Elizabeth A Chattillion; Raeanne C Moore; Susan K Roepke; Colin A Depp; Scott Roesch
Journal:  Clin Psychol Rev       Date:  2011-04-28

Review 4.  Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria.

Authors:  Sandra C van Calcar; Denise M Ney
Journal:  J Acad Nutr Diet       Date:  2012-08       Impact factor: 4.910

Review 5.  Biological and social influences on cognitive control processes dependent on prefrontal cortex.

Authors:  Adele Diamond
Journal:  Prog Brain Res       Date:  2011       Impact factor: 2.453

6.  Predictability and inconsistencies in the cognitive outcome of early treated PKU patients.

Authors:  Filippo Manti; Francesca Nardecchia; Sabrina Paci; Flavia Chiarotti; Claudia Carducci; Carla Carducci; Silvia Dalmazzone; Graziella Cefalo; Elisabetta Salvatici; Giuseppe Banderali; Vincenzo Leuzzi
Journal:  J Inherit Metab Dis       Date:  2017-08-23       Impact factor: 4.982

7.  Neurocognitive profiles in MSUD school-age patients.

Authors:  Juliette Bouchereau; Julie Leduc-Leballeur; Samia Pichard; Apolline Imbard; Jean-François Benoist; Marie-Thérèse Abi Warde; Jean-Baptiste Arnoux; Valérie Barbier; Anaïs Brassier; Pierre Broué; Aline Cano; Brigitte Chabrol; Gilles Damon; Claire Gay; Isabelle Guillain; Florence Habarou; Delphine Lamireau; Chris Ottolenghi; Laetitia Paermentier; Frédérique Sabourdy; Guy Touati; Hélène Ogier de Baulny; Pascale de Lonlay; Manuel Schiff
Journal:  J Inherit Metab Dis       Date:  2017-03-21       Impact factor: 4.982

8.  Brain White Matter Integrity Mediates the Relationship Between Phenylalanine Control and Executive Abilities in Children with Phenylketonuria.

Authors:  Anna Hood; Jerrel Rutlin; Joshua S Shimony; Dorothy K Grange; Desiree A White
Journal:  JIMD Rep       Date:  2016-07-22

9.  White matter integrity and executive abilities in individuals with phenylketonuria.

Authors:  Jo Ann V Antenor-Dorsey; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

10.  Executive dysfunction in treated phenylketonuric patients.

Authors:  Bahare Azadi; Arshia Seddigh; Mehdi Tehrani-Doost; Javad Alaghband-Rad; Mahmoud Reza Ashrafi
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-16       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.